Venn Life Sciences is a European CRO with over 24 years’ experience in the management & resourcing of clinical trials. We have worked acrosss all phases of clinical research, with extensive experience in multiple therapeutic and device areas.

We have worked with leading pharmaceutical, biotech and medical device companies seeking to navigate the often difficult European clinical trial landscape. We have senior management teams that have worked internationally on a range of different trial sizes, who are directly involved in the preparation, management and implemention of study activities.

Over the years our high rate of repeat business highlights our commitment to give our clients a service that is over and above what is expected of a CRO. We understand the importance of fair pricing, attention to detail and consistency in terms of project teams. These qualities are what make us a leading CRO in Europe and with just under 300 trials completed, we have the capabilities to place therapeutically aligned clinical staff on all our sponsor projects.



http://vennlifesciences.com/

EUR 2m contract with leading European biotech
RNS
RNS Number : 8174P
Venn Life Sciences Holdings PLC
10 June 2015

10 June 2015

Venn Life Sciences Holdings Plc

("Venn" or the "Company" or the "Group")



Venn Signs €2m Contract with Leading European Biotech



Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology, academic and medical device clients, announces today the signing of a €2m contract with a leading European Biotechnology company.



The Phase III study, in the area of Rheumatology, will cover multiple European countries, commences immediately and will run over 4 years with a high concentration of activity in year one. Venn has extensive experience in the management of Phase III trials with an excellent track record of multi-site and multi-cultural clinical trials. The contract win comes on the back of Venn reporting a 140% revenue increase in 2014 and €4.1m of new contracts in March of this year with a US based Biotechnology company.



Speaking about the agreement, Venn CEO, Tony Richardson stated: "The signing of this contract reinforces the continued success of our clinical and business development teams to win projects with leading international organisations. Venn has been steadily and continuously delivering on its strategy to win larger multi country scale contracts and to increase its footprint across Europe."

proactiveinvestors ,venn-life-sciences-riding-the-biotech-wave

Trading update
RNS
RNS Number : 8992V
Venn Life Sciences Holdings PLC
13 August 2015



Venn Life Sciences Holdings Plc

("Venn" the "Company" or the "Group")



Trading update



Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces a strong first half of 2015 with the Company billing in excess of €4m, up 170% against the same period in 2014 (H1: €1.5m).



The Company has demonstrated continued growth throughout 2015 driven by contract wins amounting to over €9m in the period to 30 June 2015.



Commenting on the figures, Venn CEO, Tony Richardson said: "Our fee income figures highlight the steady and consistent growth of the Company year on year with both repeat business and organic growth contributing to our excellent results and ability to win projects internationally. Our market continues to grow steadily and with a healthy pipeline of prospects we are well positioned to deliver further growth."



Venn will announce its interim results for the six months ended 30 June 2015 on the 22 September 2015.

10:25 02/11/2016
Director Deals - Venn Life Sciences Holdings PLC (VENN)
Allan Wood, Chairman, bought 230,000 shares in the company on the 31st October 2016 at a price of 21.67p. The Director now holds 230,000 shares. NOTE: Average price over 2 transactions. Story provided by StockMarketWire.com Director deals data provided by www.directorsholdings.com